Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer
A. Woolston, K. Khan, G. Spain, L. J. Barber, B. Griffiths, R. Gonzalez Exposito, Y. Patil, S. Mansukhani, M. N. Davies, A. Furness, F. Sclafani, C. Peckitt, K. Kouvelakis, R. Ranftl, R. Begum, , M. Gerlinger
The paper analyzes genomic and transcriptomic data from CRC patients treated with cetuximab to identify resistance mechanisms and immune landscape changes during anti-EGFR therapy.
bioRxiv · Oct 19, 2018Cancer Biology